-
Apr 23 |
Diagnostics World | Over the past few years, a multidisciplinary team of experts has been spreading the news that an abnormality of the heart’s left atrium (LA), known as LA myopathy, can be a marker of elevated risk of stroke and dementia—even in the absence of atrial fibrillation (AFib). The current “gap in the field” is that there is no established way to characterize the condition.
More
-
Apr 22 |
Diagnostics World | The clinical relevance and limitations of so-called “lab-in-a-box” (LIAB) diagnostics, which surged in popularity during the COVID pandemic, have since that time been under considerable scrutiny, most notably among investors still spooked by the notorious Theranos scandal. One of the more enduring problems among LIAB developers is that they tend to get “blinded by the beauty” of their technology.
More
-
Apr 17 |
Diagnostics World | Researchers at The University of Texas at El Paso (UTEP) are developing a point-of-care device for diagnosing colorectal cancer which, like blood glucose devices, uses electrochemical sensors. The microchip electrode features an immunosensor that detects disease biomarkers in a drop of blood, opening the possibility of an accessible, inexpensive test for the nation’s second leading cause of cancer-related deaths.
More
-
Apr 16 |
Diagnostics World | Magnetic flexible endoscopes (MFEs) have up to now had a few disadvantages limiting their use inside the human body for performing virtual biopsies, notably navigation-related difficulties related to their traditional cylindrical shape. These robot-assisted devices use magnetic forces to propel and maneuver through lumens like the colon, but rotation happens in only two directions that limits the scope's ability to effectively perform procedures.
More
-
Apr 15 |
Diagnostics World | The “bioenergetic capacity” of individuals, as marked by the level of certain cognition-associated molecules in the blood, could potentially be predictive of the risk of developing Alzheimer’s and other age-related diseases. A simulated clinical trial suggests that turning back the wheels on that biological clock could be just as effective at slowing cognitive decline as the latest drug to be approved for that purpose by the U.S. Food and Drug Administration.
More
-
Apr 10 |
Diagnostics World | Researchers worldwide are looking to revamp traditional approaches to medical imaging and develop alternative solutions that could improve visualization, speed, and accuracy in diagnostic settings. At the University of Arkansas, for example, one group is developing an AI tool designed to help radiologists and doctors analyze chest X-rays and computed tomography (CT) scans, with an emphasis on understanding how the AI assistant arrives at its conclusions.
More
-
Apr 08 |
Diagnostics World | The impact of the throat microbiome on the health of older individuals has gone unappreciated, especially among individuals being cared for in long-term care facilities. One big reason is that they are largely isolated and often forgotten by the public, even as these facilities have become home to a greater proportion of the overall population.
More
-
Apr 04 |
Diagnostics World | Atrial Fibrillation (AFib) is a fast-growing public health crisis—three times more common than once thought. Today, at least 10.55 million US adults have AFib, far exceeding the 3.3 million cases researchers predicted for the year 2020 in 1996. And this crisis is only growing.
More
-
Apr 03 |
Diagnostics World | Last week, Babson Diagnostics entered an agreement with Sam’s Club to offer BetterWay blood testing. BetterWay is currently available in seven Sam’s Club pharmacies in the greater Austin area. The agreement with Sam’s Club marks a significant milestone for accessible blood testing for patients.
More
-
Apr 01 |
Diagnostics World | The U.S. District Court for the Eastern District of Texas granted a motion for summary judgment yesterday, vacating the FDA rule that would have regulated LDTs as medical devices under the Federal Food, Drug and Cosmetic Act.
More
-
Apr 24 |
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing diagnostic challenges associated with axSpA. AxSpA is an inflammatory autoimmune condition of the spine, often misdiagnosed as persistent lower back pain for 7–10 years before accurate detection. Earlier diagnosis is essential to prevent irreversible spinal damage and to improve outcomes. SPINEstat™ offers physicians an objective, clinically validated biomarker to support early and accurate axSpA diagnosis, marking a major advancement in autoimmune diagnostics across the UK.
More
-
Apr 24 |
More
-
Apr 24 |
Predictive Power of IsoPSA Is Sustained For Over Two Years; Data Strengthens Evidence for IsoPSA’s Accuracy in Prostate Cancer Detection & Patient Risk Assessment
More
-
Apr 22 |
Hospital-acquired infections (HAIs) remain a major concern in healthcare, causing significant morbidity, mortality, and increased hospital costs. Despite advancements in infection control, HAIs continue to affect millions of patients annually, often due to antibiotic-resistant pathogens.
More
-
Apr 18 |
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune condition impacting the spine, axSpA often goes undiagnosed, mistaken for persistent lower back pain for 7-10 years before an accurate diagnosis. There is an urgent need to decrease the diagnostic delay for axSpA. If untreated, axSpA is a highly debilitating disease that causes irreversible spinal fusion leading to reduced mobility and quality of life. It can strike at any age, but typically begins before age 45, during the most productive years of a person’s life.
More
-
Apr 18 |
More
-
Apr 16 |
CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.
More
-
Apr 16 |
VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform
More
-
Apr 15 |
Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.
More
-
Apr 11 |
Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.
More
View more articles